Jubilant Pharma Limited announces launchof 145JUBIR146 remdesivir in India for the treatment of OVID Noida UP India Monday August 20Jubilant Pharma Limited a subsidiary of Jubilant Life ID: 828156
Download Pdf The PPT/PDF document "JUBILANT PHARMA LIMITED(Company Registra..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
JUBILANT PHARMA LIMITED(Company Registra
JUBILANT PHARMA LIMITED(Company Registration No. 200506887H)(Incorporated in the Republic of Singapore)Registered office: 80 Robinson Road, #02Singapore Exchange Securities Trading Limited11 North BuonaVista Drive #06The Metropolis Tower 2Dear Sirs,our letter dated July 20, 2020 intimating about approval of R’ (remdesivir)e enclose a communication pertaining tolaunch of ‘JUBI(remdesivir)in India for the treatment of COVIDWe request you to take the same on record.Thanking you,Yours Faithfully,For Jubilant Pharma LimitedSd/Shyam S. BhartiaChairman and Managing DirectorEncl.: As above Jubilant Pharma Limited announces launchof ‘JUBIR’ (remdesivir)in India for the treatment of OVIDNoida (UP), India, Monday, August, 20Jubilant Pharma Limited, a subsidiary of Jubilant LifeSciences Limited, Jubilant Pharma Ltd. 6 Temasek Boulevard, #20Suntec City Tower Four,Singapore 038986Tel.: +
62354129 www.jubilantpharma.com
62354129 www.jubilantpharma.com About Jubilant Pharma LimitedJubilant Pharma Limited (JPL), a company incorporated under the laws of Singapore and awhollyowned subsidiary of Jubilant Life Sciences Limited, is an integrated global Pharmaceutical company engaged in manufacturing and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Contract Manufacturing of terile Injectables and Non terile products through sixUSFDA approved manufacturing facilities in the US, Canada and India and a network of over 50 radiopharmacies in the US. The Company has a team of around5,200 multicultural people across the globe andis committed to deliver value to its customers spread across over 75 countries. It is well recognized as a 'Partner of Choice' by leading pharmaceuticalcompanies globallyStatements in this document relating to future status, events, or circumstances, i
ncluding but not limited to statements a
ncluding but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forwardlooking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forwardlooking statements. Jubilant may, from time to time, make additional written and oral forward looking statements, including statements contained in the company’s filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forwardlooking statements to reflect actual results, changed assumptions or other factor